Nov 07, 2019
Global Contact Lens Markets, 2015-2018 & 2019-2025 - Key Players are Alcon, Cooper Vision, Valeant Pharmaceuticals, Johnson & Johnson
Jun 26, 2018
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA(TM) (lofexidine)
Jun 19, 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX
Jun 18, 2018
FDA Issues Complete Response Letter For DUOBRII(TM) (Halobetasol Propionate and Tazarotene) Lotion
May 17, 2018
Valeant Announces Pricing Of Private Offering Of Notes
May 17, 2018
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
May 15, 2018
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
May 10, 2018
Valeant To Seek Refinancing of its Existing Credit Agreement
May 10, 2018
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
May 08, 2018
Valeant Will Become Bausch Health Companies Inc.
May 08, 2018
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
May 03, 2018
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
Apr 12, 2018
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
Apr 10, 2018
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
Apr 06, 2018
Valeant Will Release First-Quarter 2018 Financial Results On May 8
Mar 12, 2018
Valeant Announces Launch Of Private Offering Of Senior Notes
Mar 12, 2018
Valeant Announces Pricing of Private Offering of Senior Notes
Mar 08, 2018
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
Feb 27, 2018
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
Feb 06, 2018
Periodontal Therapeutics Market, 2025 - Key Companies are 3M, Valeant Pharmaceuticals, Inc., Kaken Pharmaceuticals Co. Ltd., Den-Mat Holdings, LLC, Dexcel Pharma and Galderma S.A.